Bill
Expedited Access to Biosimilars Act This bill modifies statutory requirements for demonstrating that a proposed biological product (e.g., a drug or vaccine) is biosimilar to a reference (brand-name) product. Specifically, the bill…
Overview and Timeline are the same for every version. Text and Votes below change with the version you select.
Introduced in Senate — Apr 10, 2025
congress.gov did not return a machine-readable document, but the official printed PDF is available.